ArticleOPEN ACCESS

Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype

Journal of Neuropathology and Experimental Neurology
DOI: 10.1093/jnen/nlad082
5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Shelbourn, A., Nuechterlein, N., Parada, C. A., Eaton, J., Tucker, M., Ferreira, M., & Cimino, P. J. (2023, December 1). Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype. Journal of Neuropathology and Experimental Neurology. Oxford University Press. https://doi.org/10.1093/jnen/nlad082

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free